Usefulness of Simple Original Interstitial Lung Abnormality Scores for Predicting Radiation Pneumonitis Requiring Steroidal Treatment After Definitive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer

Tairo Kashihara, Yuko Nakayama, Kimiteru Ito, Yuko Kubo, Kae Okuma, Satoshi Shima, Satoshi Nakamura, Kana Takahashi, Koji Inaba, Naoya Murakami, Hiroshi Igaki, Yuichiro Ohe, Masahiko Kusumoto, Jun Itami, Tairo Kashihara, Yuko Nakayama, Kimiteru Ito, Yuko Kubo, Kae Okuma, Satoshi Shima, Satoshi Nakamura, Kana Takahashi, Koji Inaba, Naoya Murakami, Hiroshi Igaki, Yuichiro Ohe, Masahiko Kusumoto, Jun Itami

Abstract

Purpose: Adjuvant durvalumab has become a standard treatment after chemoradiation therapy for patients with locally advanced non-small cell lung cancer (LA-NSCLC). Accordingly, predicting radiation pneumonitis (RP) requiring steroidal treatment (steroid-RP) is of utmost importance because steroidal administration is reported to weaken the effectiveness of immunotherapy. However, grade 2 RP was used as an index of RP in previous studies, but it is an ambiguous definition because it includes not only steroid-RP but also a mild cough requiring only a cough medicine. Therefore, in this study, steroid-RP was used for evaluating RP, and the purpose of this study was to investigate predictive factors of steroid-RP, including original simple interstitial lung abnormality scores (ILASs).

Methods and materials: A total of 145 patients with LA-NSCLC who received definitive radiation therapy (DRT) in our institution from January 2014 to May 2017 were identified. Original ILASs, performance status, age, respiratory function, Brinkman index, concurrent administration of chemotherapy, and dose-volume histogram metrics of the lung were analyzed to evaluate their association with steroid-RP. Additionally, 3 diagnostic radiologists evaluated the patients' pre-DRT chest computed tomography images and determined the simple ILASs. ILASs were rated as follows: 0: none; 1: abnormality without honeycombing (ground-glass attenuation, fine reticular opacity, and microcysts); and 2: honeycombing.

Results: The median follow-up period was 729 days. Thirty-one patients (21.4%) experienced steroid-RP. In the univariate analysis, lung V5/V10/VS5, Brinkman index, and ILASs were significant predictive factors of steroid-RP. Additionally, multivariate analysis including Brinkman index ≥840, lung V5 ≥37%, and an ILAS ≥1 revealed that only an ILAS (P = .001) was an independent predictive factor of steroid-RP.

Conclusions: The original simple ILAS was an easy-to-use tool and a significant predictive factor of steroid-RP in DRT in patients with LA-NSCLC.

© 2020 The Authors.

Figures

Figure 1
Figure 1
Examples of original interstitial lung abnormality scores: 0, none (left); 1, interstitial lung abnormality without honeycombing (ground-glass attenuation, fine reticular opacity, and microcysts) (middle); 2, honeycombing (right).
Figure 2
Figure 2
Kaplan–Meier survival curves of radiation pneumonitis not requiring steroids by interstitial lung abnormality scores (blue line: 0; red line: 1; green line: 2).

References

    1. Antonia S.J., Villegas A., Daniel D. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–1929.
    1. Antonia S.J., Villegas A., Daniel D. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342–2350.
    1. Gray J.E., Villegas A., Daniel D. Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage IIINSCLC - update from PACIFIC. J Thorac Oncol. 2020;15:288–293.
    1. Arbour K.C., Mezquita L., Long N. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018;36:2872–2878.
    1. Giles A.J., Hutchinson M.N.D., Sonnemann H.M. Dexamethasone-induced immunosuppression: Mechanisms and implications for immunotherapy. J Immunother Cancer. 2018;6:51.
    1. Palma D.A., Senan S., Tsujino K. Predicting radiation pneumonitis after chemoradiotherapy for lung cancer: An international individual patient data metaanalysis. Int J Radiat Oncol Biol Phys. 2013;85:444–450.
    1. Li F., Zhou Z., Wu A. Preexisting radiological interstitial lung abnormalities are a risk factor for severe radiation pneumonitis in patients with small-cell lung cancer after thoracic radiation therapy. Radiat Oncol. 2018;13:82.
    1. Kwa S.L., Lebesque J.V., Theuws J.C. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 1998;42:1–9.
    1. Marks L.B., Bentzen S.M., Deasy J.O. Radiation dose volume effects in the lung. Int J Radiat Oncol Biol Phys. 2010;76:S70–S76.
    1. Kharofa J., Cohen E.P., Tomic R. Decreased risk of radiation pneumonitis with incidental concurrent use of angiotensin-converting enzyme inhibitors and thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84:238–243.
    1. Sio T.T., Atherton P.J., Pederson L.D. Daily lisinopril vs placebo for prevention of chemoradiation-induced pulmonary distress in patients with lung cancer (Alliance MC1221): A pilot double-blind randomized trial. Int J Radiat Oncol Biol Phys. 2019;103:686–696.
    1. Su Q., Wang D., Yuan B. Effects of proton pump inhibitors on lung cancer precise radiotherapy-induced radiation pneumonitis. Cell Biochem Biophys. 2014;70:1113–1117.
    1. Tsujino K., Hashimoto T., Shimada T. Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrentchemoradiotherapy for locally advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9:983–990.
    1. Ozawa Y., Abe T., Omae M. Impact of preexisting interstitial lung disease on acute, extensive radiation pneumonitis: Retrospective analysis of patients with lung cancer. PLoS One. 2015;10
    1. Feng M., Moran J.M., Koelling T. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011;79:10–18.
    1. Lind P.A., Marks L.B., Hollis D. Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury. Int J Radiat Oncol Biol Phys. 2002;54:340–347.
    1. Brire T.M., Krafft S., Liao Z. Lung size and the risk of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2016;94:377–384.
    1. Zhang X.J., Sun J.G., Sun J. Prediction of radiation pneumonitis in lung cancer patients: a systematic review. J Cancer Res Clin Oncol. 2012;138:2103–2116.
    1. Claude L., Pérol D., Ginestet C. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol. 2004;71:175–181.
    1. Lee Y.H., Kim Y.S., Lee S.N. Interstitial lung change in pre-radiation therapy computed tomography is a risk factor for severe radiation pneumonitis. Cancer Res Treat. 2015;47:676–686.
    1. Sanuki N., Ono A., Komatsu E. Association of computed tomography-detected pulmonary interstitial changes with severe radiation pneumonitis for patients treated with thoracic radiotherapy. J Radiat Res. 2012;53:110–116.
    1. Naidoo J., Wang X., Woo K.M. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709–717.
    1. Tay R.Y., Califano R. Checkpoint inhibitor pneumonitis - real-world incidence and risk. J Thorac Oncol. 2018;13:1812–1814.
    1. Le T., Minna J.D., Gerber D.E. Checkpoint inhibitor pneumonitis: too clinically serious for benefit? J Thorac Oncol. 2019;14:332–335.
    1. Suresh K., Psoter K.J., Voong K.R. Impact of checkpoint inhibitor pneumonitis on survival in NSCLC patients receiving immune checkpoint immunotherapy. J Thorac Oncol. 2019;14:494–502.
    1. Khunger M., Rakshit S., Pasupuleti V. Incidence of pneumonitis with use of programmed death 1 and programmed death-ligand 1 inhibitors in non-small cell lung cancer. Chest. 2017;152:271–281.
    1. Margolin K.P., Ernstoff M.S., Hamid O. Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol. 2012;13:459–465.
    1. Mavroidis P., Shi C., Plataniotis G.A. Comparison of the helical tomotherapy against the multileaf collimator-based intensity-modulated radiotherapy and 3D conformal radiation modalities in lung cancer radiotherapy. Br J Radiol. 2011;84:161–172.
    1. Chun S.G., Hu C., Choy H. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: A secondary analysis of the NRG Oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35:56–62.
    1. Kong M., Hong S.E. Comparison of survival rates between 3D conformal radiotherapy and intensity-modulated radiotherapy in patients with stage III non-small cell lung cancer. Onco Targets Ther. 2016;9:7227–7234.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren